<DOC>
	<DOCNO>NCT01341912</DOCNO>
	<brief_summary>The purpose study study long-term efficacy , safety tolerability Human-cl rhFVIII previously treat patient severe hemophilia A .</brief_summary>
	<brief_title>Study Investigate Long-term Efficacy Safety Human-cl rhFVIII Previously Treated Patients ( PTPs )</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Completion GENA01 study least 50 Exposure Days ( EDs ) least 6 month study participation immediate enrollment GENA11 Development FVIII inhibitor ( &lt; =0.6 BU ) , course GENA01 study Development severe liver kidney disease ( ALT AST level &gt; 5 time upper limit normal , creatine &gt; 120 micro mol/L ) course GENA01 study</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>